CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Injury Prevention is a peer-reviewed academic journal published by the prestigious BMJ Publishing Group, dedicated to advancing the field of public health, especially in the realm of preventing injuries. With an ISSN of 1353-8047 and an E-ISSN of 1475-5785, this journal stands out as a critical resource within its domain, reflecting its significant impact as evidenced by its Q1 ranking in Public Health, Environmental and Occupational Health, according to the latest 2023 metrics. Covering a wide array of topics from epidemiology to policy implications, Injury Prevention fosters the exchange of innovative research and effective strategies to reduce injuries on a global scale. The journal has been published continuously since 1995 and will continue its commitment to excellence through 2024. Researchers, professionals, and students alike will benefit from its rich content that reflects current trends and advancements in injury prevention methodologies. Although it currently does not offer Open Access options, its high ranking, with a Scopus rank of #170 out of 665 in its category and sitting at the 74th percentile, underscores its importance in informing and influencing best practices for public health initiatives worldwide. For those looking to contribute to or stay informed on critical advancements in the field, Injury Prevention remains an indispensable resource.

Colorectal Cancer is an esteemed academic journal published by Taylor & Francis Ltd, focusing on all aspects of colorectal cancer research, diagnosis, treatment, and prevention. With an ISSN of 1758-194X and an E-ISSN of 1758-1958, this journal serves as a critical platform for publishing innovative studies, clinical trials, and meta-analyses to advance the understanding of colorectal cancer. Though not yet categorized under open access, it provides valuable insights and is committed to enhancing the visibility of research contributions within the field. The journal aims to foster collaboration and communication among researchers, clinicians, and students dedicated to improving patient outcomes and exploring novel therapeutic strategies. With its rigorous editorial standards, Colorectal Cancer plays a pivotal role in shaping future research and clinical practices, making it indispensable for professionals in oncology, gastroenterology, and related fields.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Open Medicine, with ISSN 2391-5463 and E-ISSN 2391-5463, is a distinguished peer-reviewed journal published by De Gruyter Poland Sp. z o.o, focusing on a broad array of topics in the field of medicine. Since its inception in 2013, the journal has maintained an Open Access policy, fostering the dissemination of scientific knowledge across global audiences and promoting collaborative research efforts. Based in Germany, Open Medicine has established itself within the medical community, achieving a respectable Q3 ranking in the category of Medicine (Miscellaneous) as of 2023, and placing in the 72nd percentile in general medicine according to Scopus rankings. The journal aims to bridge gaps in research by offering a platform for innovative studies, clinical trials, and comprehensive reviews that advance medical knowledge and practice. With a commitment to enhancing accessibility and visibility of research, Open Medicine plays a vital role in encouraging the continued development of the medical field, making it an essential resource for researchers, professionals, and students alike.

Middle East Journal of Cancer, with an ISSN of 2008-6709 and an E-ISSN of 2008-6687, is a prominent open-access journal published by Shiraz University of Medical Sciences since 2010. Based in Iran, the journal aims to advance the knowledge and understanding of cancer research and oncology through the dissemination of high-quality, peer-reviewed articles. With open access availability, it promotes global collaboration and accessibility in research, making findings readily available to a wider audience. The journal is categorized in Q4 for both Cancer Research and Oncology as of 2023, highlighting its emerging presence in these fields. Alongside its Scopus ranks, where it positions 319th out of 404 in Medicine - Oncology and 198th out of 230 in Biochemistry, Genetics and Molecular Biology - Cancer Research, it serves as a platform for researchers, professionals, and students to enrich their expertise and contribute to the evolving landscape of cancer studies. The journal's continuous commitment to quality and accessibility represents an essential resource for those dedicated to advancing cancer research and improving patient outcomes in the Middle East and beyond.

ADDICTION, published by Wiley, is a highly regarded academic journal that serves the vibrant fields of Medicine and Psychiatry and Mental Health. With an impressive impact factor reflective of its significance—ranking in the top 8% and 7.5% of its categories respectively—this journal is esteemed for its rigorous peer-reviewed research which spans a wide array of topics related to addiction, including pharmacology, prevention, and treatment modalities. Since its inception in 1993, ADDICTION has continually provided a platform for innovative research, shaping the discourse and influencing clinical practices worldwide. This journal, based in the United Kingdom at a prestigious location in Hoboken, NJ, stands as a beacon for researchers, practitioners, and students alike, committed to advancing understanding and strategies to combat addiction-related challenges. Although it is not an Open Access publication, the journal's contribution to the field remains invaluable, ensuring that cutting-edge findings are disseminated widely among professionals dedicated to improving mental health outcomes.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.